Across TCGA pan-cancer cohorts, KLHDC2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated KLHDC2 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher KLHDC2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KLHDC2 expression acts as an unfavorable survival marker.
KICH are the cancer types where KLHDC2 Mutation most reproducibly stratifies survival.